Germany · Delayed Price · Currency is EUR Selvita Company Description
Selvita S.A. operates as a contract research organization worldwide.
The company offers drug discovery services in the areas of AI-driven drug discovery, antibody drug discovery, structural biology, recombinant protein production, assay development and screening, computer-aided drug design, medicinal and synthetic chemistry, scale-up, ADME/DMPK, in vitro and In Vivo pharmacology, translational research, and toxicology.
It also develops drugs for therapeutic areas, such as oncology, infectious diseases, immunology, neurology, respiratory, and other.
In addition, the company provides drug development services, including formulation development; CMC analytical support; stability and shelf-life determination; clinical supply/GMP manufacturing; small molecules bioanalysis; drug substance and product; and biologics and biosimilars bioanalysis services.
Further, it offers research and development services in the areas of agrochemistry analytical support, and flavor and fragrance chemistry.
The company was formerly known as Selvita CRO S.A. and changed its name to Selvita S.A. in October 2019.
Selvita S.A. was founded in 2007 and is based in Kraków, Poland.
| Country | Poland |
| Founded | 2007 |
| Industry | Commercial Physical and Biological Research |
| Employees | 969 |
| CEO | Boguslaw Sieczkowski |
Contact Details
Address: Hexagon Kraków, 30-394 Poland | |
| Phone | 48 123 00 50 01 |
| Website | selvita.com |
Stock Details
| Ticker Symbol | 787 |
| Exchange | Frankfurt Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | PLN |
| SIC Code | 8731 |
Key Executives
| Name | Position |
|---|---|
| Boguslaw Sieczkowski | Chief Executive Officer |
| Dariusz Kurdas | Chief Financial Officer |